Image for Gradientech presents QuickMIC® results at ECCMID
IR Press releases 2023-04-14

Gradientech presents QuickMIC® results at ECCMID

Uppsala, Sweden, 14 April 2023. Gradientech announces that it will present promising results from two collaborative studies of its ultra-rapid and precise diagnostic system QuickMIC® at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark 15 - 18 April 2023.

“We are very pleased to showcase our QuickMIC system for leading experts in the field. QuickMIC is the fastest phenotypic AST system for sepsis samples on the market today with results available within 2-4 hours from positive blood culture. In combination with its precise linear MIC results, we believe we are taking AST to a whole new level of clinical utility”, says Sara Thorslund, CEO of Gradientech.

On 17 April at 14:45 Gradientech’s Chief Scientist Christer Malmberg will present results from the clinical performance evaluation study “A multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections”.

“I am honoured for this opportunity to share our data from the recent multicenter study of our QuickMIC ultra-rapid AST system with the audience at ECCMID, one of the world’s leading conferences within this field. The results are promising, and the novel technology shows favourable results with low variability and high reproducibility between clinical laboratories”, says Christer Malmberg.

Gradientech’s poster will display results from an exciting collaborative study: “A rapid workflow for bacterial isolation and phenotypic AST directly from blood”, conducted with Momentum BioScience and Uppsala University. The study combined the QuickMIC system with Momentum BioScience’s SepsiPURE® technology, to explore a new workflow without conventional blood culture. 

The QuickMIC system and its Gram-negative panel are CE-marked and commercially available in Europe but not FDA 510(k)-cleared and not available for sale in the United States.

For further information, please contact:

Sara Thorslund, PhD, CEO Gradientech

Tel: +46 736 29 35 80


Peter Karlberg, VP Sales Gradientech

Tel: +46 763 29 08 14


About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC® allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala. Visit for more information.